Latest Biotech News

Angelini Pharma is buying Catalyst Pharmaceuticals for about $4.1 billion in cash, securing a foothold in the U.S. rare-disease market and expanding its neurology presence. The deal values...

Bayer agreed to acquire Perfuse Therapeutics for $300 million up front, with the total potential value reaching $2.45 billion, as the German drugmaker looks to broaden its ophthalmology pipeline....

Avalo Therapeutics reported Phase 2 success for abdakibart in hidradenitis suppurativa, meeting the trial’s primary endpoint on the HiSCR75 response rate at week 16 in the Lotus study. Shares...

Moderna has started a clinical trial for an experimental mRNA vaccine designed to prevent Lyme disease, enrolling about 350 healthy adults aged 18 to 70 in a randomized, placebo-controlled study....

UCB agreed to acquire Candid Therapeutics for up to $2.2 billion, extending its presence in T-cell engager (TCE) antibodies for autoimmune and inflammatory indications. The deal adds Candid’s lead...

BillionToOne reported a sharp jump in Q1 2026 revenue, driven by increased prenatal clinical testing volume. Revenue rose 84% year over year to $108.4 million, while prenatal testing contributed...

Switzerland’s privately funded biotech sector reported record capital generation and hiring activity in 2025, according to an industry report. Private biotechs raised CHF 1.15 billion (US$1.47...

CellCentric raised $220 million in a Series D round to advance an oral multiple myeloma therapy into late-stage development. The company said the capital is intended to complete a Phase 2 study...

Mayo Clinic and Stanford Medicine unveiled a blood test designed to chart the tumor “neighborhood” by profiling the tumor microenvironment more directly than conventional liquid biopsy approaches....

Prolific Machines said its light-controlled biomanufacturing platform more than doubled fed-batch antibody titers, reporting 21 g/L in a 15-day intensified run for a monoclonal antibody. The...

Bayer agreed to acquire Perfuse Therapeutics for up to $2.45 billion, betting on ophthalmology assets led by PER-001, an endothelin receptor antagonist delivered as a slow-release, dissolvable...

Novo Nordisk reported that its GLP-1 obesity pill is starting faster than expected and lifted guidance, signaling improving demand momentum ahead of competitive pressure in the class. The company...

Tempus reported a 36% year-over-year jump in Q1 revenue and raised full-year guidance, supported by growth in its diagnostics business and higher minimal residual disease (MRD) testing volume. The...

BillionToOne posted a sharp Q1 revenue increase of 84% year over year, driven by higher prenatal clinical testing volume and faster growth in oncology assays. The company reported Q1 2026 revenue...

Madrigal Pharmaceuticals continued its metabolic dysfunction–associated steatohepatitis (MASH) strategy with another genetic-medicine deal, licensing an Arrowhead siRNA asset aimed at a defined...

Private investment in Swiss biotechs reached a record CHF 1.15 billion in 2025, increasing 38% versus 2024, according to Swiss biotech tracking data. The report also said the 2025 figure...

Moonlight AI raised $3.3 million in private financing as it builds software to extract genomic biomarkers and disease signatures from routine imaging of blood and cytology smears. The Swiss...

GSK licensed an siRNA asset, SA-030, from Suzhou Siran Biotechnology in a deal with potential value up to $1 billion. The siRNA program has entered Phase I trials for cardiometabolic disease,...

ChromaGenix, a gene-therapy manufacturing spinout from North Carolina State University, commercialized peptide ligands intended to simplify affinity purification of viral vectors. The company said...

South Korea’s Ministry of Food and Drug Safety approved Curocell’s CAR T therapy Rimqarto (anbal-cel) as the first homegrown CAR T product for advanced diffuse large B-cell lymphoma. The approval,...